Drugs / Ezabenlimab
Trials 28 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03433898 | Feb 2018 → Jul 2023 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 121 trials | ||||||
| Phase 1 | NCT07607678 | May 2026 → Jun 2028 expected | metastatic malignant neoplasm | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT07395258 | Apr 2026 → Feb 2028 | cancer | Boehringer Ingelheim | Suspended | No outcome recorded |
| Phase 1 | NCT06091930 | Feb 2024 → Aug 2025 | colorectal cancer, head and neck cancer, liver cancer, lung cancer +1 | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05846516 | May 2023 → Mar 2027 expected | pancreatic ductal adenocarcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05446129 | Sep 2022 → Aug 2023 | colorectal cancer | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT05327946 | May 2022 → Jul 2024 overdue | cancer | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05249426 | Apr 2022 → Jul 2024 | head and neck squamous cell carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05155332 | Mar 2022 → Dec 2027 | cancer | Boehringer Ingelheim | Suspended | No outcome recorded |
| Phase 1 | NCT04958239 | Oct 2021 → Apr 2026 overdue | neoplasm | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04752215 | May 2021 → Nov 2024 | cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04653142 | Dec 2020 → Apr 2022 | cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04147234 | Aug 2020 → Nov 2022 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04046445 | Jul 2019 → May 2025 overdue | metastasis from malignant tumor of colon, rectal cancer | Amal Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03964233 | Jun 2019 → Sep 2024 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03972150 | Jun 2019 → Oct 2020 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03990233 | Apr 2019 → Apr 2023 | cancer | OSE Immunotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03468426 | Jul 2018 → Jul 2024 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03383978 | Dec 2017 → Dec 2027 expected | glioblastoma | Johann Wolfgang Goethe University Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT03166631 | Sep 2017 → Sep 2020 | metastatic neoplasm, non-small cell lung carcinoma | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT03156114 | Jun 2017 → Mar 2023 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02952248 | Nov 2016 → Apr 2021 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06084689 | Jun → Jul 2024 | biliary tract cancer, colorectal cancer, non-small cell lung carcinoma, soft tissue sarcoma +1 | Institut Bergonié | Withdrawn | No outcome recorded |
| Phase 2 | NCT04719988 | Jan 2022 → Nov 2024 overdue | anal squamous cell carcinoma | Centre Hospitalier Universitaire de Besancon | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04839471 | Aug 2021 → Jul 2023 | esophageal squamous cell carcinoma | National Health Research Institutes, Taiwan | Completed | No outcome recorded |
| Phase 2 | NCT04499352 | Sep → Oct 2020 | anal canal squamous cell carcinoma | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 2 | NCT03697304 | Mar 2019 → Dec 2024 | metastatic neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06370871 | Jun 2024 → Jul 2026 | myxofibrosarcoma, undifferentiated pleomorphic sarcoma | Boehringer Ingelheim | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05879978 Background | Jun 2023 → Jun 2025 overdue | small cell lung carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05471856 Background | Feb 2023 → Sep 2028 expected | cancer | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT05068102 Background | Mar 2022 → Sep 2026 expected | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03780725 Background | Jan 2019 → Feb 2020 | head and neck squamous cell carcinoma, non-small cell lung carcinoma | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ezabenlimab | “Ezabenlimab (BI 754091) and mDCF (Docetaxel, Cisplatin and 5-fluorouracil) Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.” NCT04719988 ↗21“immune checkpoint inhibitor, ezabenlimab (BI 754091)” PMID 35699077 ↗ Jun 2022 |
| Known as | BI 754091 | “Ezabenlimab (BI 754091) and mDCF (Docetaxel, Cisplatin and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.” NCT04719988 ↗16“240 mg Ezabenlimab (BI 754091) as an intravenous infusion on day 1 of each 3-week cycle.” NCT03468426 ↗ “The study tests 2 medicines called BI 765049 and ezabenlimab (BI 754091).” NCT04752215 ↗ “immune checkpoint inhibitor, ezabenlimab (BI 754091)” PMID 35699077 ↗ Jun 2022 “the anti-PD-1 antibody Ezabenlimab (BI 754091)” NCT03383978 ↗ “anti-PD-1 antibody ezabenlimab (BI 754091)” PMID 35756842 ↗ Jun 2022 “Ezabenlimab (BI 754091)” NCT07607678 ↗ |
| Action | Inhibit | “Ezabenlimab bound with high affinity to human PD-1 (KD = 6 nM) and blocked the interaction of PD-1 with PD-L1 and PD-L2.” PMID 35756842 ↗ Jun 2022 |
| Modality | Monoclonal antibody | “the anti-PD-1 antibody Ezabenlimab (BI 754091)” NCT03383978 ↗ |
| Route | Intravenous | “240 mg ezabenlimab given as an intravenous infusion” NCT03156114 ↗ |